Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 14/20 | 0.53 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31644771 | 0.96 | HCRTR1 (0.49) | HCRTR1HCRTR2CASP3TSHRHSD11B1 | |
| SCHEMBL31644657 | 0.84 | KMT2A (0.64) | HCRTR1HCRTR2CASP3TSHRKMT2A | |
| SCHEMBL31644589 | 0.82 | HCRTR1 (0.56) | HCRTR1HCRTR2CASP3TSHRKMT2A | |
| SCHEMBL4609883 | 0.81 | ACLY (0.55) | HCRTR1HCRTR2CASP3HSD11B1 | |
| SCHEMBL31644712 | 0.79 | CASP3 (0.54) | HCRTR1HCRTR2CASP3KMT2A | |
| SCHEMBL31645394 | 0.79 | CASP3 (0.49) | HCRTR1HCRTR2CASP3TSHRKMT2A | |
| SCHEMBL31644694 | 0.78 | RORC (0.51) | HCRTR1HCRTR2CASP3TSHRHSD11B1 | |
| SCHEMBL31644477 | 0.76 | KMT2A (0.63) | HCRTR1HCRTR2TSHRKMT2A | |
| SCHEMBL31644755 | 0.76 | HCRTR1 (0.69) | HCRTR1HCRTR2CASP3TSHRKMT2A | |
| SCHEMBL3901904 | 0.76 | ITGB1 (0.59) | HCRTR1HCRTR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025132542-A1 | MACROCYCLIC OREXIN AGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-06-26 | — | — | WO | disclosed |